ImmunityBio Stock
ImmunityBio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard Gerald Adcock
- Employees
- 688
- Market cap
- $9.7 B
- IPO
- 28/07/2015
ImmunityBio, Inc. is a clinical-stage biotechnology firm based in San Diego, USA, founded in 2014. The company focuses on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
ImmunityBio stock: price history
1D
-8.2%
1W
-12.7%
1M
+16.1%
6M
+19.2%
YTD
+363.6%
1Y
+262.8%
2Y
+147.4%
5Y
-1.3%
10Y
+37.0%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~65% stronger price swings than usual
ImmunityBio stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
ImmunityBio is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for treating cancer and infectious diseases. Its portfolio encompasses technology platforms including antibody-cytokine fusion proteins, synthetically manufactured immunomodulators, vaccine technologies, and NK cell therapies. Research activities are directed against diverse tumor types such as bladder, pancreatic, and lung cancer, as well as pathogens including SARS-CoV-2 and HIV. The company is positioned through various Phase II and III clinical trials as well as strategic partnerships and licensing agreements with institutions and other pharmaceutical companies.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about ImmunityBio
Analyst assessment of ImmunityBio
PRICE TARGET LOW
US$12.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 15/10/2026
ImmunityBio stock metrics
P/E
-9.43
P/B
-9.21
EV/EBITDA
-11.72
RETURN ON EQUITY
22.0%
NET MARGIN
-449.6%
DEBT/EQUITY
-0.78
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
10.9%
FLOAT SHARES
115,196,180
AVG. DAILY VOLUME (30D)
14,283,874
Insider transactions (SEC)
Simon Barry J.
Cohen Cheryl
Cohen Cheryl
Selecky Christobel
Selecky Christobel
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -8.2%
Search (Google Trends)
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about ImmunityBio stock
What does ImmunityBio do?
ImmunityBio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard Gerald Adcock, the company employs around 688 people.
The IPO was on 28/07/2015; the stock trades on NASDAQ under the ticker IBRX.
What do analysts say about ImmunityBio stock?
5 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$14.00, ranging from US$12.00 to US$16.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does ImmunityBio report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 65% stronger than usual.
Does ImmunityBio pay a dividend?
No, ImmunityBio currently does not pay a dividend.
Which stocks are comparable to ImmunityBio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ImmunityBio stock analyzed?
Clicking "Analyze stock" lets five strategies assess ImmunityBio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.